Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
CanSino Biologics, Inc. Class H ( (HK:6185) ) has provided an announcement.
CanSino Biologics has initiated a Phase I clinical trial for its DTcP-Hib-MCV4 combined vaccine, which targets diphtheria, tetanus, acellular pertussis, Haemophilus influenzae type b and meningococcal groups ACYW135, and has completed enrollment of the first patient. The trial, designed to evaluate safety and immunogenicity in children aged two months to six years, is part of the company’s strategy to expand its combined vaccine portfolio and secure a differentiated competitive position in the pediatric vaccine market, though the company cautioned investors to exercise care when trading its shares at this stage of development.
The most recent analyst rating on (HK:6185) stock is a Sell with a HK$37.00 price target. To see the full list of analyst forecasts on CanSino Biologics, Inc. Class H stock, see the HK:6185 Stock Forecast page.
More about CanSino Biologics, Inc. Class H
CanSino Biologics Inc. is a China-based biopharmaceutical company specializing in the research, development and commercialization of innovative vaccines, with a product pipeline focused on addressing major infectious diseases and meeting growing domestic and global demand for advanced immunization solutions.
Average Trading Volume: 796,552
Technical Sentiment Signal: Sell
Current Market Cap: HK$13B
For detailed information about 6185 stock, go to TipRanks’ Stock Analysis page.